Yeah, that's what I'm hoping. The CAR-T CD19 aspect of the treatment could potentially be was used as a 2nd phase type treatment at a low dose after the tumour load had been reduced. They could use the B Cell platform and CF-33 as part of an initial 1st phase treatment. It doesn't need to be eradicated first up and the combo therapies could be designed to successively target the tumours with different approaches until hopefully NED (those magic words I'm sure every cancer patient wants to hear, No Evidence of Disease).
Ann: IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS, page-323
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.001(2.44%) |
Mkt cap ! $312.4M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.3¢ | 4.1¢ | $672.3K | 16.04M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 4003556 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 197261 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |